Envivo Bio’s CapScan device profiles human gut microbiome and metabolome in study
11 May 2023
Microbial therapy
CapScan is said to be a non-invasive, ingestible collection device with a pH-targeted enteric coating and is made to disintegrate at a predetermined rate as per the various pH levels of the intestines
CapScan can enable biopharmaceutical drug discovery and development programmes. (Credit: Business Wire/Envivo Bio)
Envivo Bio has announced that its CapScan intestinal sampling device can accurately and non-invasively pro human gut microbiome and metabolome under physiological conditions for the first time in a study.
CapScan is said to be a non-invasive, ingestible collection device a size of a vitamin tablet. Every device has a pH-targeted enteric coating and is made to disintegrate at a predetermined rate as per the various pH levels of the intestines.
CapScan’s internal bladder opens and pulls in luminal fluid once this coating dissolves, which is subsequently examined outside the body.
The findings, published in the British weekly scientific journal Nature, demonstrate that the CapScan device is the first and only device of its kind that has the potential to accelerate microbiome-related research. The device will also enable biopharmaceutical drug discovery and development programmes.
Envivo Bio said that researchers from many universities have defined the capabilities of CapScan to measure viral, microbial, proteomic, and bile acid profiles in the human intestines during normal digestion in the Nature article.
In the article, the researchers reported significant differences in gene-class abundance, microbiome composition, prophage induction, and the host proteome along various regions of the human intestine.
Furthermore, the results identified and measured microbes and metabolites that are absent in stool or are not accessible through endoscopic sampling.
Envivo Bio CEO and founder Dari Shalon said: “Our research confirms that, up until now, studies of the gut microbiome have really been studies of the stool microbiome, which missed out on most of the biological activity in our intestinal tract.
“By enabling researchers to sample and assess each of the diverse intestinal ecosystems separately and directly for the first time, CapScan opens the door to a new era of microbiome research.”
In a similar development, the company reported that the new data published in Nature Metabolism shows that the CapScan intestinal sampling device can offer spatial and temporal insights into the metabolome in the upper intestinal tract.
The researchers found around 1,900 metabolites, including sulfonolipids and fatty acid esters of hydroxy fatty acids (FAHFA) lipids.
Additionally, they identified the link between metabolites and dietary biomarkers, luminal keto acids, and fruit intake, Envivo Bio said.
For more details,please visit the original website
The content of the article does not represent any opinions of Synapse and its affiliated companies. If there is any copyright infringement or error, please contact us, and we will deal with it within 24 hours.
Organizations
Indications
-Targets
-Drugs
-Chat with Hiro
Hot reports
Get started for free today!
Accelerate Strategic R&D decision making with Synapse, PatSnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.
Start your data trial now!
Synapse data is also accessible to external entities via APIs or data packages. Empower better decisions with the latest in pharmaceutical intelligence.